16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
Clinical trial NCT02294227 · COMPLETED
Trial details
- NCT number
- NCT02294227
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-29
- Primary completion
- 2016-02-16
- Enrollment
- 341
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.